ArticleBMC anesthesiology2026
Mesenchymal stromal cells alleviate neuropathic pain in association with M2 macrophage polarization in dorsal root ganglia and peripheral nerve repair.
Article in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundNeuropathic pain (NP) is a debilitating condition with limited effective treatments. Mesenchymal stromal cells (MSCs) have emerged as a potential therapeutic strategy due to their immunomodulatory properties. This study investigated whether intravenous administration of human umbilical cord-derived MSCs could alleviate NP in a rat chronic constriction injury (CCI) model and explored the associated changes in macrophage polarization and nerve structure.
methodsMale Sprague Dawley rats were subjected to CCI of the sciatic nerve and randomly divided into Control, CCI, and CCI+MSCs groups (n = 10/group). The CCI+MSCs group received 1 × 10⁶ MSCs via tail vein injection on postoperative day 7. Mechanical withdrawal threshold (MWT) and thermal withdrawal latency (TWL) were assessed at baseline and on postoperative days 1, 3, 5, 7, 10, and 15. On day 15, dorsal root ganglia (DRG) were collected for immunofluorescence staining of CD68 (pan-macrophage marker) and CD206 (M2 marker), and sciatic nerves were examined by hematoxylin-eosin staining and transmission electron microscopy (TEM).
resultsCCI induced significant mechanical and thermal hypersensitivity from postoperative day 7 through day 15 (p < 0.05 vs. Control). MSC administration partially restored MWT and TWL values compared with the CCI group (p < 0.05). Immunofluorescence revealed increased CD68⁺ macrophage infiltration in the DRG of CCI rats, which was attenuated by MSC treatment. Concurrently, CD206 expression was enhanced in the CCI+MSCs group, suggesting a shift toward an M2-like macrophage phenotype. Histological and ultrastructural analyses showed that MSC treatment was associated with reduced inflammatory cell infiltration, increased Schwann cell counts, lower G-ratio, and improved myelin sheath integrity compared with the untreated CCI group (p < 0.05).
conclusionsIntravenous MSC administration was associated with attenuation of nociceptive hypersensitivity, enhanced M2-like macrophage polarization in the DRG, and partial structural repair of the injured sciatic nerve in a rat CCI model. These findings suggest that MSCs may represent a promising cell-based approach for NP treatment, although further studies are needed to establish causal mechanisms and evaluate long-term safety and efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.